{"title":"纳武单抗与依维莫司治疗晚期肾细胞癌","authors":"C. Weight","doi":"10.1093/MED/9780190655341.003.0022","DOIUrl":null,"url":null,"abstract":"This chapter summarizes the findings of the landmark CheckMate 025 trial for the new class of drugs of immune checkpoint blockade in advanced renal cell cancer. The trial randomized patients with metastatic renal cell carcinoma who had failed antiangiogenic therapy to systemic therapy with nivolumab versus everolimus and found improved overall survival and fewer treatment-related adverse events in the nivolumab arm.","PeriodicalId":435097,"journal":{"name":"50 Studies Every Urologist Should Know","volume":"45 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":"{\"title\":\"Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma\",\"authors\":\"C. Weight\",\"doi\":\"10.1093/MED/9780190655341.003.0022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This chapter summarizes the findings of the landmark CheckMate 025 trial for the new class of drugs of immune checkpoint blockade in advanced renal cell cancer. The trial randomized patients with metastatic renal cell carcinoma who had failed antiangiogenic therapy to systemic therapy with nivolumab versus everolimus and found improved overall survival and fewer treatment-related adverse events in the nivolumab arm.\",\"PeriodicalId\":435097,\"journal\":{\"name\":\"50 Studies Every Urologist Should Know\",\"volume\":\"45 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"50 Studies Every Urologist Should Know\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/MED/9780190655341.003.0022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"50 Studies Every Urologist Should Know","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/MED/9780190655341.003.0022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
This chapter summarizes the findings of the landmark CheckMate 025 trial for the new class of drugs of immune checkpoint blockade in advanced renal cell cancer. The trial randomized patients with metastatic renal cell carcinoma who had failed antiangiogenic therapy to systemic therapy with nivolumab versus everolimus and found improved overall survival and fewer treatment-related adverse events in the nivolumab arm.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
